Quotes 5-day view Delayed Nasdaq
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
9.04(c)
9.18(c)
8.85(c)
9.69(c)
9.48(c)
Last
339 228
250 789
290 722
712 028
603 340
Volume
-5.14% +1.55% -3.59% +9.49% -2.17% Change
Sales 2020
-
-
-
Net income 2020
-170 M - -
Net cash position 2020
150 M - -
P/E ratio 2020
-4,50x
Yield 2020
-
Sales 2021
-
-
-
Net income 2021
-187 M - -
Net cash position 2021
193 M - -
P/E ratio 2021
-4,69x
Yield 2021
-
Capitalization
767 M 767 M -
EV / Sales 2020
-
EV / Sales 2021
-
Nbr of Employees
197
Free-Float
90,8%
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes,...
Notations Surperformance© of Rubius Therapeutics, Inc.
Trading Rating : Investor Rating : -
All news about RUBIUS THERAPEUTICS, INC.
News in other languages on RUBIUS THERAPEUTICS, INC.
- No features available -
Analyst Recommendations on RUBIUS THERAPEUTICS, INC.
Chart RUBIUS THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends RUBIUS THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
7
Average target price
9,57 $
Last Close Price
9,48 $
Spread / Highest target
195%
Spread / Average Target
0,96%
Spread / Lowest Target
-68,4%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
